Discontinued — last reported Q1 '26
Januvia — Sales
Merck & Co. Januvia — Sales decreased by 39.2% to $367.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 66.5%, from $1.10B to $367.00M. Over 4 years (FY 2021 to FY 2025), Januvia — Sales shows a downward trend with a -16.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market retention or successful lifecycle management, while a decrease often signals the impact of generic competition, loss of exclusivity, or shifting clinical treatment paradigms.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific pharmaceutical product line within th...
Peer comparison
Comparable to product-specific revenue reporting in other large-cap pharmaceutical companies, particularly those managing mature or 'blockbuster' drug portfolios facing patent cliffs.
mrk_segment_januvia_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.57B | $1.70B | $1.76B | $1.56B | $1.51B | $1.43B | $1.12B | $1.10B | $1.02B | $1.16B | $1.10B | $838.00M | $809.00M | $556.00M | $465.00M | $1.10B | $743.00M | $764.00M | $604.00M | $367.00M |
| QoQ Change | — | +8.7% | +3.2% | -11.4% | -3.0% | -5.2% | -21.8% | -1.8% | -7.4% | +13.7% | -5.7% | -23.5% | -3.5% | -31.3% | -16.4% | +135.9% | -32.3% | +2.8% | -20.9% | -39.2% |
| YoY Change | — | — | — | — | -3.6% | -15.8% | -36.2% | -29.3% | -32.5% | -19.0% | -2.4% | -24.0% | -20.8% | -52.1% | -57.5% | +30.9% | -8.2% | +37.4% | +29.9% | -66.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s januvia — sales?
- Merck & Co. (MRK) reported januvia — sales of $367.00M in Q1 2026.
- How has Merck & Co.'s januvia — sales changed year-over-year?
- Merck & Co.'s januvia — sales decreased by 66.5% year-over-year, from $1.10B to $367.00M.
- What is the long-term trend for Merck & Co.'s januvia — sales?
- Over 4 years (2021 to 2025), Merck & Co.'s januvia — sales has grown at a -16.7% compound annual growth rate (CAGR), from $6.65B to $3.21B.
- What does januvia — sales mean?
- Total revenue generated from the sales of a specific pharmaceutical product.